A study to investigate VT-1129 for the treatment of cryptococcal meningitis

Trial Profile

A study to investigate VT-1129 for the treatment of cryptococcal meningitis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs VT 1129 (Primary)
  • Indications Cryptococcal meningitis
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2016 According to a Viamet Pharmaceuticals media release, the US FDA has granted Fast Track Designation for VT-1129 for the treatment of cryptococcal meningitis. It has also granted Orphan Drug Designation and Qualified Infectious Disease Product designation to VT-1129.
    • 01 Jun 2016 According to a Viamet Pharmaceuticals media release, status changed from planning to recruiting.
    • 19 Sep 2015 According to a Viamet Pharmaceuticals media release, the company expect to initiate this trial in the fourth quarter of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top